Suzhou Industrial Park

Home page > category report > Industries & Enterprises


New drug against BAIs enters clinical trial in the USA


Date:   |   Source:       Font Size:    A   A   A

TenNor Therapeutics in SIP announced on Aug 2 that its new injection targeting biofilm-associated infections (BAIs) related with indwelling medical devices has advanced into Phase II clinical trial in the United States.

TenNor Therapeutics, founded in 2013 in BioBAY, a biomedicine cluster in SIP, is a clinical stage company focusing on development of antibacterial drugs to address major unmet medical needs. It raised US$25 million in Series B financing in 2016 to develop TNP-2092 series of antibiotics.

The new drug, TNP-2092 injection, has demonstrated excellent bactericidal activity and low antibiotic resistance frequency in animal testing and in vitro experiments. It is expected to be a lower-cost substitute for existing therapies that rely on operations to cure BAIs.

Suzhou Daily
August 3, 2018